Zortress
Advance Directives, Steroid therapy, Carcinoid Tumor + 11 more
Treatment
22 FDA approvals
0 Active Studies for Zortress
Treatment for
Advance Directives
What is Zortress
Everolimus
The Generic name of this drug
Treatment Summary
Everolimus is a drug related to sirolimus (Rapamycin) that works by blocking a protein called mTORC1. It is used to prevent organ rejection in transplant patients. Unlike other mTOR inhibitors, Everolimus only targets the mTORC1 protein and not the mTORC2 protein.
Afinitor
is the brand name
Zortress Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Afinitor
Everolimus
2009
59
Approved as Treatment by the FDA
Everolimus, also known as Afinitor, is approved by the FDA for 22 uses including Kidney Transplant Rejection and unresectable gastrointestinal origin Progressive Neuroendocrine Tumors .
Kidney Transplant Rejection
Used to treat Kidney Transplant Rejection in combination with Basiliximab
unresectable gastrointestinal origin Progressive Neuroendocrine Tumors
Subependymal giant cell astrocytoma, tuberous sclerosis complex
locally advanced lung origin Progressive Neuroendocrine Tumors
Tuberous Sclerosis
Neuroendocrine Tumors
Tuberous Sclerosis
Lung
metastatic lung origin Progressive Neuroendocrine Tumors
pancreatic origin Progressive Neuroendocrine Tumors
Liver Transplant Rejection
Used to treat Liver Transplant Rejection in combination with Tacrolimus
metastatic gastrointestinal origin Progressive Neuroendocrine Tumors
unresectable lung origin Progressive Neuroendocrine Tumors
locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors
Advance Directives
Used to treat refractory, advanced Breast cancer in combination with Exemestane
Renal angiomyolipoma, tuberous sclerosis complex
refractory Advanced Renal Cell Carcinoma
Neuroendocrine Tumors
Neoplasm Metastasis
Neuroendocrine Tumors
Steroid therapy
Used to treat Steroid therapy in combination with Tacrolimus
Neuroendocrine Tumors
Effectiveness
How Zortress works in the body
Everolimus stops cells from multiplying by blocking the mTOR protein. This protein is responsible for helping cells grow and divide, but when blocked by everolimus, the cells cannot move forward with their growth. Everolimus also prevents cells from creating new blood vessels and using glucose for energy. As a result, cell multiplication and growth are significantly reduced.
When to interrupt dosage
The prescribed amount of Zortress is contingent upon the diagnosed condition, such as metastatic lung origin Progressive Neuroendocrine Tumors, Heart and Advance Directives. The amount of dosage may vary, depending on the method of delivery (e.g. Tablet or Oral) detailed in the table beneath.
Condition
Dosage
Administration
Advance Directives
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
Steroid therapy
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
Carcinoid Tumor
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
Tuberous Sclerosis
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
Tuberous Sclerosis
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
Waldenstrom Macroglobulinemia
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
refractory Advanced Renal Cell Carcinoma
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
Neoplasm Metastasis
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
pancreatic origin Progressive Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
Lung
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral
Warnings
There are 20 known major drug interactions with Zortress.
Common Zortress Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Everolimus is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Everolimus is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Everolimus.
Abetimus
Major
The risk or severity of adverse effects can be increased when Everolimus is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Everolimus is combined with Acteoside.
Zortress Toxicity & Overdose Risk
The median dose of this drug required to inhibit cell growth is 0.63 nanomoles.
Zortress Novel Uses: Which Conditions Have a Clinical Trial Featuring Zortress?
16 active clinical trials are assessing the capacity of Zortress to mitigate locally advanced lung origin Progressive Neuroendocrine Tumors, advanced Carcinoid tumor and Cardiac disorders.
Condition
Clinical Trials
Trial Phases
pancreatic origin Progressive Neuroendocrine Tumors
0 Actively Recruiting
Steroid therapy
0 Actively Recruiting
Carcinoid Tumor
0 Actively Recruiting
Tuberous Sclerosis
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
refractory Advanced Renal Cell Carcinoma
0 Actively Recruiting
Tuberous Sclerosis
0 Actively Recruiting
Neuroendocrine Tumors
0 Actively Recruiting
Neuroendocrine Tumors
0 Actively Recruiting
Neuroendocrine Tumors
0 Actively Recruiting
Neuroendocrine Tumors
0 Actively Recruiting
Waldenstrom Macroglobulinemia
0 Actively Recruiting
Neoplasm Metastasis
0 Actively Recruiting
Lung
0 Actively Recruiting
Zortress Reviews: What are patients saying about Zortress?
5
Patient Review
2/21/2011
Zortress for Prevent Kidney Transplant Rejection
5
Patient Review
7/24/2020
Zortress for Prevention of Liver Transplant Rejection
3.7
Patient Review
4/26/2016
Zortress for Prevention of Liver Transplant Rejection
3.3
Patient Review
11/5/2018
Zortress for Prevention of Liver Transplant Rejection
3
Patient Review
10/10/2021
Zortress for Prevention of Liver Transplant Rejection
3
Patient Review
6/1/2016
Zortress for Prevention of Liver Transplant Rejection
2.3
Patient Review
7/25/2013
Zortress for Prevention of Liver Transplant Rejection
Patient Q&A Section about zortress
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is zortress an immunosuppressant?
"It works by slowing down the body's immune response.
Zortress prevents the body from rejecting a transplanted organ by slowing down the body's immune response."
Answered by AI
Is zortress the same as everolimus?
"Everolimus (Zortress) is an immunosuppressant drug used to prevent rejection in organ transplant patients. It is typically used in conjunction with other immunosuppressive drugs."
Answered by AI
What are the side effects of zortress?
"Common symptoms of COVID-19 include constipation, diarrhea, headache, nausea, vomiting, sores in the mouth/throat, swelling in your legs/ankles/feet, and tiredness."
Answered by AI
What is zortress used for?
"ZORTRESS is used to prevent the body from attacking a transplanted kidney or liver. This medicine is taken to prevent transplant rejection, which occurs when the body's immune system sees the new organ as a foreign object and attempts to destroy it."
Answered by AI